Our Renal Clinical Development Advisory Board

Colin Orford is a senior leader and experienced drug developer with 33 years of experience across GSK, Novartis, Quintiles, Eisai, and ICON. He combines scientific strategy with operational execution and is well-networked across biotech, pharma, and the pharmaceutical investment community. With 22 years of hands-on pharmaceutical development experience and 10 years leading ICON’s Drug Development team, Colin has spearheaded R&D project teams from preclinical through Phase IIIb, transitioning numerous molecules from candidate selection to late phase development. He has deep expertise in neurosciences, particularly in depression, anxiety, Alzheimer’s, and sleep disorders. Colin brings strong knowledge of regulatory guidelines for US, EU, and Japan markets, and expertise in due diligence for asset acquisition and investment funding. He has successfully guided Phase III teams through NDA and MAA submissions and works with emerging modalities such as cell and gene therapy.

Professor Barratt’s research is focused on a bench to bedside approach to improving understanding of the pathogenesis of IgAN. He is the IgAN Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases and a Convener of the International IgAN Network. He is Chief Investigator for multiple international randomized controlled IgAN clinical trials and was a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgAN Work group. He is an Editorial Board member for Kidney International and the Journals of the American Society of Nephrology and is co-Chair of the UK Glomerulonephritis Clinical Study Group.

Professor Wheeler’s research focuses on the management of CKD. He is Professor of Kidney Medicine, University College London and Honorary Consultant Nephrologist, the Royal Free Hospital. He has participated in the development and running of several large-scale clinical trials testing therapeutic interventions in kidney disease. He has developed clinical practice guidelines for several organizations, most recently KDIGO, of which he has served as Co-Chair. He has completed a term as Chair of the International Society of Nephrology Advancing Clinical Trials Committee and is Deputy Chair of the ISN’s Western Europe Regional Board. He is currently England’s National Institute for Health Research National Specialty Lead for Renal disorders.

Dr. Lafayette’s research interests include glomerular disease with a focus on IgA nephropathy. He is Professor of Medicine (Nephrology) at the Stanford University Medical Center and founder and director of the Stanford Glomerular Disease Center and its fellowship training program. His longstanding focus on IgA nephropathy has led to many evaluations and some elucidation of the pathogenesis of IgA nephritis and leadership in many clinical trials. He has more than 30 years of clinical experience and remains passionate in efforts to discover safer and more effective treatments.

Dr. Liew focuses on glomerular diseases, peritoneal dialysis, kidney transplantation, and diabetic kidney disease. He is Senior Consultant Nephrologist and Director of The Kidney & Transplant Practice at the Mount Elizabeth Novena Hospital, Singapore; the current elected secretary and executive of the International Society for Peritoneal Dialysis; current member of the executive committee for the KDIGO organization; and Deputy Chair of the Continuing Medical Education Committee for the ISN. A global Scientific Leader with roots in APAC, he is the only Singaporean appointed to the KDIGO working groups on Diabetes Management in Chronic Kidney Disease, and Update on Glomerular Diseases.